HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Pfizer deals extend patent life for a top-selling rare disease drug

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam. 

By PharmaVoice · Apr 30, 2026 · via PharmaVoice
Pfizer deals extend patent life for a top-selling rare disease drug

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
dealsformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
DealsFiercePharma ↗
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema…
May 2, 2026
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
DealsFierceBiotech ↗
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
May 1, 2026
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
DealsBriefing
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
AstraZeneca resumes its shelved £300M UK expansion after rebate relief and a U.S.-U.K. pharma pact, signaling …
May 1, 2026